November 22, 2017
1 min read
Save

FDA grants fast track designation to lumateperone for schizophrenia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Intra-Cellular Therapies Inc. recently announced the FDA granted fast track designation for lumateperone for treatment of schizophrenia.

Lumateperone is a dopamine receptor phosphoprotein modulation that provides selective and simultaneous modulation of serotonin, dopamine and glutamate.

Safety and efficacy of lumateperone were evaluated in three randomized, double-blind, placebo-controlled studies.

In two studies, lumateperone was statistically significantly separate from placebo at the primary endpoint, Positive and Negative Syndrome Scale total score.

Lumateperone was well-tolerated and had a similar safety profile to placebo in all three studies.

“We are pleased with the FDA’s designation of lumateperone for Fast Track development,” Sharon Mates, PhD, chairman and CEO of Intra-Cellular Therapies, said in a press release. “Given the important safety and tolerability limitations of existing antipsychotics, we believe that lumateperone may represent a significant advance in the treatment of schizophrenia.”